Clinical Cancer Research AACR Conference on Cancer Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rangel, L. B. A.
Right arrow Articles by Morin, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rangel, L. B. A.
Right arrow Articles by Morin, P. J.
Clinical Cancer Research Vol. 9, 2567-2575, July 2003
© 2003 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Tight Junction Proteins Claudin-3 and Claudin-4 Are Frequently Overexpressed in Ovarian Cancer but Not in Ovarian Cystadenomas

Leticia B. A. Rangel1, Rachana Agarwal1, Theresa D’Souza, Ellen S. Pizer, Piero L. Alò, Wayne D. Lancaster, Lucie Gregoire, Donald R. Schwartz, Kathleen R. Cho and Patrice J. Morin2

Laboratory of Cellular and Molecular Biology, Gerontology Research Center, National Institute on Aging, Baltimore, Maryland 21224 [L. B. A. R., R. A., T. D., P. J. M.]; Department of Basic and Clinical Pharmacology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil [L. B. A. R.]; Dipartimento di Medicina Sperimentale e Patologia, Università di Roma, Rome, Italy [P. L. A.]; Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan 48201 [W. D. L., L. G.]; Department of Pathology, The University of Michigan Medical School, Ann Arbor, Michigan 48109 [D. R. S., K. R. C.]; and Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287 [E. S. P., P. J. M.]

Purpose: Claudin proteins represent a large family of integral membrane proteins crucial for tight junction (TJ) formation and function. Claudins have been shown to be up-regulated in various cancers and have been suggested as possible biomarkers and targets for cancer therapy. Because claudin-3 and claudin-4 have been proposed to be expressed in epithelial ovarian cancer, we have performed a detailed analysis of CLDN3 and CLDN4 expression in a panel of ovarian tumors of various subtypes and cell lines. We also investigated whether high expression of claudin-3 and claudin-4 was associated with TJ function in ovarian cancer cells.

Experimental Design: RNA was obtained from a panel of 39 microdissected epithelial ovarian tumors of various histological subtypes for real-time reverse transcription-PCR analysis. In addition, a total of 70 cases of ovarian carcinomas, ovarian cysts, and normal ovarian epithelium from a tissue array were analyzed by immunohistochemistry. Finally, a panel of cell lines was used for Western analysis of claudin expression and TJ permeability studies.

Results: Although expressed at low levels in some normal human tissues, including the ovary, CLDN3 and CLDN4 are highly up-regulated in epithelial ovarian cancers of all subtypes. Immunohistochemical analyses using our ovarian tissue array confirmed the high level of expression of claudin-3 and claudin-4 in the majority of ovarian carcinomas, including many tumors exhibiting cytoplasmic staining. Ovarian cystadenoma did not frequently overexpress these proteins, suggesting that the expression of these proteins is associated with malignancy. In ovarian cancer cell lines, claudin-3 and claudin-4 expression was not associated with functional TJs as measured by transepithelial electrical resistance.

Conclusions: These results show that CLDN3 and CLDN4 are frequently up-regulated in ovarian tumors and cell lines and may represent novel markers for this disease. Overexpression of these genes in ovarian cancer also suggests interesting scenarios for the involvement of TJ in tumorigenesis. A better knowledge of the mechanisms underlying ovarian tumorigenesis will likely result in the development of novel approaches for the diagnosis and therapy of this deadly disease.




This article has been cited by other articles:


Home page
J Mol EndocrinolHome page
N. Gava, C. L. Clarke, C. Bye, K. Byth, and A. deFazio
Global gene expression profiles of ovarian surface epithelial cells in vivo
J. Mol. Endocrinol., June 1, 2008; 40(6): 281 - 296.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Y. C. Ip, S. T. Cheung, Y. T. Lee, J. C. Ho, and S. T. Fan
Inhibition of hepatocellular carcinoma invasion by suppression of claudin-10 in HLE cells
Mol. Cancer Ther., November 1, 2007; 6(11): 2858 - 2867.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
S. Boireau, M. Buchert, M. S. Samuel, J. Pannequin, J. L. Ryan, A. Choquet, H. Chapuis, X. Rebillard, C. Avances, M. Ernst, et al.
DNA-methylation-dependent alterations of claudin-4 expression in human bladder carcinoma
Carcinogenesis, February 1, 2007; 28(2): 246 - 258.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
M. Lioni, P. Brafford, C. Andl, A. Rustgi, W. El-Deiry, M. Herlyn, and K. S.M. Smalley
Dysregulation of Claudin-7 Leads to Loss of E-Cadherin Expression and the Increased Invasion of Esophageal Squamous Cell Carcinoma Cells
Am. J. Pathol., February 1, 2007; 170(2): 709 - 721.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Honda, M. J. Pazin, H. Ji, R. P. Wernyj, and P. J. Morin
Crucial Roles of Sp1 and Epigenetic Modifications in the Regulation of the CLDN4 Promoter in Ovarian Cancer Cells
J. Biol. Chem., July 28, 2006; 281(30): 21433 - 21444.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
J. J. Stewart, J. T. White, X. Yan, S. Collins, C. W. Drescher, N. D. Urban, L. Hood, and B. Lin
Proteins Associated with Cisplatin Resistance in Ovarian Cancer Cells Identified by Quantitative Proteomic Technology and Integrated with mRNA Expression Levels
Mol. Cell. Proteomics, March 1, 2006; 5(3): 433 - 443.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
S. C. Cunningham, F. Kamangar, M. P. Kim, S. Hammoud, R. Haque, C. A. Iacobuzio-Donahue, A. Maitra, R. Ashfaq, S. Hustinx, R. E. Heitmiller, et al.
Claudin-4, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions.
Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 281 - 287.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. Ebihara, M. Kondoh, N. Hasuike, M. Harada, H. Mizuguchi, Y. Horiguchi, M. Fujii, and Y. Watanabe
Preparation of a Claudin-Targeting Molecule Using a C-Terminal Fragment of Clostridium perfringens Enterotoxin
J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 255 - 260.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
D. B. N. Lee, E. Huang, and H. J. Ward
Tight junction biology and kidney dysfunction
Am J Physiol Renal Physiol, January 1, 2006; 290(1): F20 - F34.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Tanaka, R. Kamata, and R. Sakai
EphA2 Phosphorylates the Cytoplasmic Tail of Claudin-4 and Mediates Paracellular Permeability
J. Biol. Chem., December 23, 2005; 280(51): 42375 - 42382.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. J. Morin
Claudin Proteins in Human Cancer: Promising New Targets for Diagnosis and Therapy
Cancer Res., November 1, 2005; 65(21): 9603 - 9606.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Agarwal, T. D'Souza, and P. J. Morin
Claudin-3 and Claudin-4 Expression in Ovarian Epithelial Cells Enhances Invasion and Is Associated with Increased Matrix Metalloproteinase-2 Activity
Cancer Res., August 15, 2005; 65(16): 7378 - 7385.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
A. H. Johnson, H. F. Frierson, A. Zaika, S. M. Powell, J. Roche, S. Crowe, C. A. Moskaluk, and W. El-Rifai
Expression of Tight-Junction Protein Claudin-7 Is an Early Event in Gastric Tumorigenesis
Am. J. Pathol., August 1, 2005; 167(2): 577 - 584.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. D'Souza, R. Agarwal, and P. J. Morin
Phosphorylation of Claudin-3 at Threonine 192 by cAMP-dependent Protein Kinase Regulates Tight Junction Barrier Function in Ovarian Cancer Cells
J. Biol. Chem., July 15, 2005; 280(28): 26233 - 26240.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. D. Santin, S. Cane, S. Bellone, M. Palmieri, E. R. Siegel, M. Thomas, J. J. Roman, A. Burnett, M. J. Cannon, and S. Pecorelli
Treatment of Chemotherapy-Resistant Human Ovarian Cancer Xenografts in C.B-17/SCID Mice by Intraperitoneal Administration of Clostridium perfringens Enterotoxin
Cancer Res., May 15, 2005; 65(10): 4334 - 4342.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. T. Cheung, K. L. Leung, Y. C. Ip, X. Chen, D. Y. Fong, I. O. Ng, S. T. Fan, and S. So
Claudin-10 Expression Level is Associated with Recurrence of Primary Hepatocellular Carcinoma
Clin. Cancer Res., January 15, 2005; 11(2): 551 - 556.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. Wang, Y. Ngalame, M. C. Panelli, H. Nguyen-Jackson, M. Deavers, P. Mueller, W. Hu, C. A. Savary, R. Kobayashi, R. S. Freedman, et al.
Peritoneal and Subperitoneal Stroma May Facilitate Regional Spread of Ovarian Cancer
Clin. Cancer Res., January 1, 2005; 11(1): 113 - 122.
[Abstract] [Full Text] [PDF]


Home page
PhysiologyHome page
C. M. Van Itallie and J. M. Anderson
The Molecular Physiology of Tight Junction Pores
Physiology, December 1, 2004; 19(6): 331 - 338.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
V. A. Heinzelmann-Schwarz, M. Gardiner-Garden, S. M. Henshall, J. Scurry, R. A. Scolyer, M. J. Davies, M. Heinzelmann, L. H. Kalish, A. Bali, J. G. Kench, et al.
Overexpression of the Cell Adhesion Molecules DDR1, Claudin 3, and Ep-CAM in Metaplastic Ovarian Epithelium and Ovarian Cancer
Clin. Cancer Res., July 1, 2004; 10(13): 4427 - 4436.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
K. Turksen and T.-C. Troy
Barriers built on claudins
J. Cell Sci., May 15, 2004; 117(12): 2435 - 2447.
[Abstract] [Full Text] [PDF]


Home page
Sci SignalHome page
J. M. Mullin
Epithelial Barriers, Compartmentation, and Cancer
Sci. Signal., January 20, 2004; 2004(216): pe2 - pe2.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.